Jean van Wyk, MBChB, MFPM, discussed the 5-year OPERA data from IDWeek 2026 as well as the anticipated CROWN study results.
|Videos|March 12, 2020
The Importance of Youth HIV Prevention
Author(s)Contagion® Editorial Staff
Colleen Kelley, MD, MPH, discusses the importance of targeted youth HIV prevention measures.
Advertisement
Segment Description: Colleen Kelley, MD, MPH, associate professor at the Emory University School of Medicine, discusses the importance of targeted youth HIV prevention measures.
Interview Transcript (modified slightly for readability):
Young individuals, especially young men who have sex with men and transgender people have highest rates of HIV infection in the US, and globally young women and girls in Africa are also at very high risk for HIV. This absolutely has to be a focus of our prevention and treatment efforts.
Young people in general tend to have a hard time accessing care and adhering to medical regimens because they have so many other things going on in their lives, including not having a mature adult brain. This has to be a population with a huge focus on for our prevention as well as our treatment interventions.
Advertisement
Related to this article
Cefiderocol MICs fell against Pseudomonas aeruginosa and Klebsiella pneumoniae, and the drug showed marked synergy with LL-37 against resistant Acinetobacter baumannii. Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses her team's findings around this therapy and these pathogens.
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Investigational asuptegravir cut HIV-1 RNA by up to 2.36 log10 copies/mL in 10 days, and adding fostemsavir boosted CD4 gains in immunologic nonresponders.
Switching to once-daily bictegravir/lenacapavir kept adverse event rates similar to comparators and metabolic markers stable across comorbidity groups in ARTISTRY-1 and -2.
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Advertisement
Advertisement
Trending on Contagion Live
1
A Closer Look at IDSA/ESCMID 2026 Consensus Statements 6 and 7 on Staphylococcus aureus Bacteremia
2
Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
3
Cefiderocol Activity Improves in Physiologic Media, Synergizes With LL-37
4
FDA Approves Voceryq, First Plasmid DNA Immunotherapy for Recurrent Respiratory Papillomatosis
5